Merck is stopping development of the company’s two Covid-19 vaccine candidates, dubbed V590 and V591, after poor responses in Phase I trials.

Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.

Precision Medicine Group acquired Project Farma, a patient-focused bioengineering services firm that supports life science innovators in the manufacturing and scale-up of advanced therapies.

French pharma giant Sanofi kicked off 2021 with a $1.4 billion cash acquisition of U.K.-based Kymab to bolster the company’s presence in immunology.

Life sciences mergers and acquisitions (M&A) activity totaled $159 billion in 2020, down from $306 billion in 2019, reaching one of the lowest levels since 2014, according to the 2021 EY M&A Firepower report

Global health innovation leader W2O announced the acquisitions of tech-enabled companies Swoop and IPM.ai, further accelerating what is expected to be the company’s 20th consecutive year of double-digit revenue growth.

France’s Servier bolstered its presence in oncology with the acquisition of the clinical and research-stage oncology business of Agios Pharmaceuticals in a deal worth up to $2 billion.

Novartis is acquiring Cambridge, Massachusetts-based neuroscience company Cadent Therapeutics for a $210 million upfront payment and potentially $560 million in milestone payments.

Shares of Prevail Therapeutics skyrocketed in trading after Eli Lilly announced the acquisition of the gene therapy company in a deal valued at $1.04 billion.

AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion, with the deal expected to close in the third quarter of 2021.